Kanter J - Search Results

1

Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.

Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, Roberts JD, Lanzkron S. Kanter J, et al. Blood Adv. 2020 Aug 25;4(16):3804-3813. doi: 10.1182/bloodadvances.2020001743. Blood Adv. 2020. PMID: 32785684 Free PMC article.

2

Management of sickle cell disease from childhood through adulthood.

Kanter J, Kruse-Jarres R. Kanter J, et al. Blood Rev. 2013 Nov;27(6):279-87. doi: 10.1016/j.blre.2013.09.001. Epub 2013 Sep 19. Blood Rev. 2013. PMID: 24094945 Free article. Review.

3

Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.

Horan JT, Haight A, Dioguardi JL, Brown C, Grizzle A, Shelman C, Kanter J, Hale G, Nieder M, Benton M, Kasow KA, Abraham A, Chiang KY. Horan JT, et al. Among authors: kanter j. Biol Blood Marrow Transplant. 2015 May;21(5):900-5. doi: 10.1016/j.bbmt.2015.01.015. Epub 2015 Jan 21. Biol Blood Marrow Transplant. 2015. PMID: 25617808 Free article. Clinical Trial.

4

Validation of a novel point of care testing device for sickle cell disease.

Kanter J, Telen MJ, Hoppe C, Roberts CL, Kim JS, Yang X. Kanter J, et al. BMC Med. 2015 Sep 16;13:225. doi: 10.1186/s12916-015-0473-6. BMC Med. 2015. PMID: 26377572 Free PMC article.

5

Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke.

Dowling MM, Quinn CT, Ramaciotti C, Kanter J, Osunkwo I, Inusa B, Iyer R, Kwiatkowski JL, Johnson C, Rhodes M, Owen W, Strouse JJ, Panepinto JA, Neumayr L, Sarnaik S, Plumb PA, Dlamini N, Kirkham F, Hynan LS; PFAST Investigators. Dowling MM, et al. Among authors: kanter j. Br J Haematol. 2017 Jan;176(2):300-308. doi: 10.1111/bjh.14391. Epub 2016 Oct 21. Br J Haematol. 2017. PMID: 27766637 Free PMC article.

6

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.

Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Ataga KI, et al. Among authors: kanter j. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. N Engl J Med. 2017. PMID: 27959701 Free PMC article. Clinical Trial.

7

Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke.

Adams RJ, Cox M, Ozark SD, Kanter J, Schulte PJ, Xian Y, Fonarow GC, Smith EE, Schwamm LH. Adams RJ, et al. Among authors: kanter j. Stroke. 2017 Mar;48(3):686-691. doi: 10.1161/STROKEAHA.116.015412. Epub 2017 Feb 9. Stroke. 2017. PMID: 28183857

8

Crizanlizumab in Sickle Cell Disease.

Ataga KI, Kutlar A, Kanter J. Ataga KI, et al. Among authors: kanter j. N Engl J Med. 2017 May 4;376(18):1796. doi: 10.1056/NEJMc1703162. N Engl J Med. 2017. PMID: 28467874 No abstract available.

9

Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.

Kanter J, Heath LE, Knorr J, Agbenyega ET, Colombatti R, Dampier C, Hassab H, Manwani D, Robitaille N, Brown PB, Jakubowski JA, Yao S, Hoppe C. Kanter J, et al. Br J Haematol. 2019 Mar;184(6):1058-1061. doi: 10.1111/bjh.15250. Epub 2018 Apr 20. Br J Haematol. 2019. PMID: 29676449 Free article. No abstract available.

10

A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. Niihara Y, et al. Among authors: kanter j. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. N Engl J Med. 2018. PMID: 30021096 Free article. Clinical Trial.

11

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial).

Daak AA, Dampier CD, Fuh B, Kanter J, Alvarez OA, Black LV, McNaull MA, Callaghan MU, George A, Neumayr L, Hilliard LM, Sancilio F, Rabinowicz AL, Heeney MM. Daak AA, et al. Among authors: kanter j. Blood Adv. 2018 Aug 14;2(15):1969-1979. doi: 10.1182/bloodadvances.2018021444. Blood Adv. 2018. PMID: 30097463 Free PMC article. Clinical Trial.

12

The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease.

DiMartino LD, Baumann AA, Hsu LL, Kanter J, Gordeuk VR, Glassberg J, Treadwell MJ, Melvin CL, Telfair J, Klesges LM, King A, Wun T, Shah N, Gibson RW, Hankins JS; Sickle Cell Disease Implementation Consortium. DiMartino LD, et al. Among authors: kanter j. Am J Hematol. 2018 Dec;93(12):E391-E395. doi: 10.1002/ajh.25282. Epub 2018 Oct 17. Am J Hematol. 2018. PMID: 30203558 Free PMC article. No abstract available.

13

Barriers to Pediatric Sickle Cell Disease Guideline Recommendations.

Cabana MD, Kanter J, Marsh AM, Treadwell MJ, Rowland M, Stemmler P, Bardach NS. Cabana MD, et al. Among authors: kanter j. Glob Pediatr Health. 2019 May 3;6:2333794X19847026. doi: 10.1177/2333794X19847026. eCollection 2019. Glob Pediatr Health. 2019. PMID: 31106244 Free PMC article.

14

An approach to revising mHealth interventions for children and families: A case example in sickle cell disease.

Phillips S, Kanter J, Ruggiero KJ, Mueller M, Johnson MA, Kelechi TJ. Phillips S, et al. Among authors: kanter j. Res Nurs Health. 2019 Dec;42(6):483-493. doi: 10.1002/nur.21973. Epub 2019 Aug 8. Res Nurs Health. 2019. PMID: 31393015 Free PMC article.

15

Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease.

Kanter J, Lanzkron S. Kanter J, et al. Clin Pharmacol Ther. 2020 Jan;107(1):140-146. doi: 10.1002/cpt.1682. Epub 2019 Nov 25. Clin Pharmacol Ther. 2020. PMID: 31617585 Review.

16

Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium.

Schlenz AM, Phillips S, Mueller M, Melvin C, Adams RJ, Kanter J; DISPLACE Investigators. Schlenz AM, et al. Among authors: kanter j. Pediatr Blood Cancer. 2020 Apr;67(4):e28172. doi: 10.1002/pbc.28172. Epub 2020 Jan 11. Pediatr Blood Cancer. 2020. PMID: 31925913 Free PMC article.

17

Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.

Hsieh MM, Bonner M, Pierciey FJ, Uchida N, Rottman J, Demopoulos L, Schmidt M, Kanter J, Walters MC, Thompson AA, Asmal M, Tisdale JF. Hsieh MM, et al. Among authors: kanter j. Blood Adv. 2020 May 12;4(9):2058-2063. doi: 10.1182/bloodadvances.2019001330. Blood Adv. 2020. PMID: 32396618 Free PMC article.

18

Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care.

Kanter J, Gibson R, Lawrence RH, Smeltzer MP, Pugh NL, Glassberg J, Masese RV, King AA, Calhoun C, Hankins JS, Treadwell M. Kanter J, et al. JAMA Netw Open. 2020 May 1;3(5):e206016. doi: 10.1001/jamanetworkopen.2020.6016. JAMA Netw Open. 2020. PMID: 32469413 Free PMC article.

19

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease.

Brazauskas R, Scigliuolo GM, Wang HL, Cappelli B, Ruggeri A, Fitzhugh CD, Hankins JS, Kanter J, Meerpohl JJ, Panepinto JA, Rondelli D, Shenoy S, Walters MC, Wagner JE, Tisdale JF, Gluckman E, Eapen M. Brazauskas R, et al. Among authors: kanter j. Blood. 2020 Jul 30;136(5):623-626. doi: 10.1182/blood.2020005687. Blood. 2020. PMID: 32518950 Free PMC article.

20

Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry.

Glassberg JA, Linton EA, Burson K, Hendershot T, Telfair J, Kanter J, Gordeuk VR, King AA, Melvin CL, Shah N, Hankins JS, Epié AY, Richardson LD; Sickle Cell Disease Implementation Consortium. Glassberg JA, et al. Among authors: kanter j. Orphanet J Rare Dis. 2020 Jul 7;15(1):178. doi: 10.1186/s13023-020-01457-x. Orphanet J Rare Dis. 2020. PMID: 32635939 Free PMC article.

21

Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium.

Phillips S, Schlenz AM, Mueller M, Melvin C, Adams RJ, Kanter J; (on behalf of the DISPLACE investigators). Phillips S, et al. Among authors: kanter j. Pediatr Blood Cancer. 2020 Nov;67(11):e28569. doi: 10.1002/pbc.28569. Epub 2020 Sep 7. Pediatr Blood Cancer. 2020. PMID: 32894002 Free PMC article.

22

A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department.

Linton EA, Goodin DA, Hankins JS, Kanter J, Preiss L, Simon J, Souffront K, Tanabe P, Gibson R, Hsu LL, King A, Richardsona LD, Glassberg JA; Sickle Cell Disease Implementation Consortium. Linton EA, et al. Among authors: kanter j. Ann Emerg Med. 2020 Sep;76(3S):S64-S72. doi: 10.1016/j.annemergmed.2020.08.013. Ann Emerg Med. 2020. PMID: 32928465 Free PMC article.

23

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.

Osunkwo I, Manwani D, Kanter J. Osunkwo I, et al. Among authors: kanter j. Ther Adv Hematol. 2020 Sep 29;11:2040620720955000. doi: 10.1177/2040620720955000. eCollection 2020. Ther Adv Hematol. 2020. PMID: 33062233 Free PMC article. Review.

24

Development of a Severity Classification System for Sickle Cell Disease.

Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, Gordeuk VR, Kanter J, Klings ES, Lipato T, Manwani D, Scullin B, Yermilov I, Smith WR. Shah N, et al. Among authors: kanter j. Clinicoecon Outcomes Res. 2020 Oct 28;12:625-633. doi: 10.2147/CEOR.S276121. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 33149635 Free PMC article.

25

Changes in Care Delivery for Children With Sickle Cell Anemia During the COVID-19 Pandemic.

Noisette ML, Phillips S, Schlenz AM, Mueller M, Kanter J. Noisette ML, et al. Among authors: kanter j. J Pediatr Hematol Oncol. 2021 Nov 1;43(8):e1231-e1234. doi: 10.1097/MPH.0000000000002008. J Pediatr Hematol Oncol. 2021. PMID: 33235147 Free PMC article.

26

Feasibility of an mHealth self-management intervention for children and adolescents with sickle cell disease and their families.

Phillips S, Kanter J, Mueller M, Gulledge A, Ruggiero K, Johnson M, Kelechi TJ. Phillips S, et al. Among authors: kanter j. Transl Behav Med. 2021 Apr 7;11(3):724-732. doi: 10.1093/tbm/ibaa132. Transl Behav Med. 2021. PMID: 33410488 Free PMC article.

27

Adaptable stewardship during a pandemic: a multifaceted approach to sustaining the blood supply for individuals with sickle cell disease.

Godby RC, Kornbrust A, Noubouossie D, Kanter J, Ogunsile FJ, Lima JLO, Singh N, Marques MB, Siniard RC. Godby RC, et al. Among authors: kanter j. Int J Lab Hematol. 2021 Aug;43(4):O168-O170. doi: 10.1111/ijlh.13485. Epub 2021 Feb 12. Int J Lab Hematol. 2021. PMID: 33576556 Free PMC article. No abstract available.

28

Kneeling Was the First Step for Sickle Cell Disease.

Desai P, Little J, Kanter J, Bridges K, Andemariam B, Lanzkron S. Desai P, et al. Among authors: kanter j. Ann Intern Med. 2021 Jul;174(7):1004-1005. doi: 10.7326/M20-7418. Epub 2021 Mar 23. Ann Intern Med. 2021. PMID: 33750189 No abstract available.

29

One Small Step for Sickle Cell Disease: Many More to Go.

Kanter J. Kanter J. Ann Intern Med. 2021 Sep;174(9):1313-1314. doi: 10.7326/M21-2650. Epub 2021 Jul 6. Ann Intern Med. 2021. PMID: 34224263 No abstract available.

30

Gaps in the diagnosis and management of iron overload in sickle cell disease: a 'real-world' report from the GRNDaD registry.

Wilson SR, Sears M, Williams E, Drapekin J, Sivakumar I, Padrino S, Desai PC, Hager W, Manwani D, Clay LJ, Field JJ, Kanter J, Cohen AJ, Saif Ur Rehman S, Lanzkron S, Little JA; GRNDaD investigators. Wilson SR, et al. Among authors: kanter j. Br J Haematol. 2021 Dec;195(5):e157-e160. doi: 10.1111/bjh.17762. Epub 2021 Aug 22. Br J Haematol. 2021. PMID: 34423416 No abstract available.

31

Which adults with sickle cell disease need an evaluation for pulmonary embolism?

El-Amin N, Lauzon SD, Nietert PJ, Kanter J. El-Amin N, et al. Among authors: kanter j. Br J Haematol. 2021 Nov;195(3):447-455. doi: 10.1111/bjh.17552. Epub 2021 Sep 1. Br J Haematol. 2021. PMID: 34472094 Free PMC article.

32

Treatment-related Correlates of Growth in Children With Sickle Cell Disease in the DISPLACE Cohort.

Galadanci NA, Sohail M, Akinyelure OP, Kanter J, Ojesina AI. Galadanci NA, et al. Among authors: kanter j. J Pediatr Hematol Oncol. 2022 Jul 1;44(5):249-254. doi: 10.1097/MPH.0000000000002296. Epub 2021 Sep 6. J Pediatr Hematol Oncol. 2022. PMID: 34486556 Free PMC article.

33

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.

Kanter J, Liem RI, Bernaudin F, Bolaños-Meade J, Fitzhugh CD, Hankins JS, Murad MH, Panepinto JA, Rondelli D, Shenoy S, Wagner J, Walters MC, Woolford T, Meerpohl JJ, Tisdale J. Kanter J, et al. Blood Adv. 2021 Sep 28;5(18):3668-3689. doi: 10.1182/bloodadvances.2021004394C. Blood Adv. 2021. PMID: 34581773 Free PMC article.

34

Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.

Liles DK, Shah NR, Scullin B, Gordeuk VR, Smith WR, Kanter J, Achebe MM, Boccia R, Crary SE, Kraft WK, Archer N, Cataldo V, Hardesty BM, Idowu M, Desai PC, Ikeda A, Puthenveetil G, Hassell KL, Sarnaik S, Kutlar A. Liles DK, et al. Among authors: kanter j. Br J Haematol. 2021 Nov;195(4):e150-e153. doi: 10.1111/bjh.17739. Epub 2021 Oct 5. Br J Haematol. 2021. PMID: 34611900 No abstract available.

35

Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium.

Masese RV, Bulgin D, Knisely MR, Preiss L, Stevenson E, Hankins JS, Treadwell MJ, King AA, Gordeuk VR, Kanter J, Gibson R, Glassberg JA, Tanabe P, Shah N; Sickle Cell Disease Implementation Consortium. Masese RV, et al. Among authors: kanter j. PLoS One. 2021 Oct 29;16(10):e0258638. doi: 10.1371/journal.pone.0258638. eCollection 2021. PLoS One. 2021. PMID: 34714833 Free PMC article.

36

Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.

Smeltzer MP, Howell KE, Treadwell M, Preiss L, King AA, Glassberg JA, Tanabe P, Badawy SM, DiMartino L, Gibson R, Kanter J, Klesges LM, Hankins JS; Sickle Cell Disease Implementation Consortium. Smeltzer MP, et al. Among authors: kanter j. BMJ Open. 2021 Nov 17;11(11):e050880. doi: 10.1136/bmjopen-2021-050880. BMJ Open. 2021. PMID: 34789492 Free PMC article.

37

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.

Kwiatkowski JL, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Alshehri A, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Tricta F, Elalfy MS. Kwiatkowski JL, et al. Among authors: kanter j. Blood Adv. 2022 Feb 22;6(4):1243-1254. doi: 10.1182/bloodadvances.2021004938. Blood Adv. 2022. PMID: 34847228 Free PMC article. Clinical Trial.

38

Gene therapy for sickle cell disease: where we are now?

Kanter J, Falcon C. Kanter J, et al. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):174-180. doi: 10.1182/hematology.2021000250. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889358 Free PMC article.

39

GRNDaD: big data and sickle cell disease.

Lanzkron S, Manwani D, Desai P, Kanter J, Little J. Lanzkron S, et al. Among authors: kanter j. Blood Adv. 2022 Feb 8;6(3):1088. doi: 10.1182/bloodadvances.2021005282. Blood Adv. 2022. PMID: 35133406 Free PMC article.

40

Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.

Kroner BL, Hankins JS, Pugh N, Kutlar A, King AA, Shah NR, Kanter J, Glassberg J, Treadwell M, Gordeuk VR; Sickle Cell Disease Implementation Consortium. Kroner BL, et al. Among authors: kanter j. Am J Hematol. 2022 May;97(5):603-612. doi: 10.1002/ajh.26495. Epub 2022 Feb 17. Am J Hematol. 2022. PMID: 35142007 Free PMC article.

41

Perspectives of individuals with sickle cell disease on barriers to care.

Phillips S, Chen Y, Masese R, Noisette L, Jordan K, Jacobs S, Hsu LL, Melvin CL, Treadwell M, Shah N, Tanabe P, Kanter J. Phillips S, et al. Among authors: kanter j. PLoS One. 2022 Mar 23;17(3):e0265342. doi: 10.1371/journal.pone.0265342. eCollection 2022. PLoS One. 2022. PMID: 35320302 Free PMC article.

42

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.

Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, Åstrand M, Maklad N, Niazi M, Himmelmann A, Berggren AR. Heeney MM, et al. Among authors: kanter j. Blood. 2022 Sep 29;140(13):1470-1481. doi: 10.1182/blood.2021014095. Blood. 2022. PMID: 35849650 Free PMC article. Clinical Trial.

43

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.

Dampier CD, Telen MJ, Wun T, Brown RC, Desai P, El Rassi F, Fuh B, Kanter J, Pastore Y, Rothman J, Taylor JG, Readett D, Sivamurthy KM, Tammara B, Tseng LJ, Lozier JN, Thackray H, Magnani JL, Hassell KL; RESET Investigators. Dampier CD, et al. Among authors: kanter j. Blood. 2023 Jan 12;141(2):168-179. doi: 10.1182/blood.2022015797. Blood. 2023. PMID: 35981565 Free article. Clinical Trial.

44

An evaluation of cardiopulmonary endurance and muscular strength in adults living with sickle cell disease.

Ogunsile FJ, Stewart KJ, Kanter J, Lanzkron SM. Ogunsile FJ, et al. Among authors: kanter j. Br J Haematol. 2022 Nov;199(4):597-602. doi: 10.1111/bjh.18436. Epub 2022 Sep 2. Br J Haematol. 2022. PMID: 36052816

45

Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center.

Hulbert ML, Manwani D, Meier ER, Alvarez OA, Brown RC, Callaghan MU, Campbell AD, Coates TD, Frei-Jones MJ, Hankins JS, Heeney MM, Hsu LL, Lebensburger JD, Quinn CT, Shah N, Smith-Whitley K, Thornburg C, Kanter J. Hulbert ML, et al. Among authors: kanter j. Pediatr Blood Cancer. 2023 Jan;70(1):e29961. doi: 10.1002/pbc.29961. Epub 2022 Sep 12. Pediatr Blood Cancer. 2023. PMID: 36094289

46

Hemorrhagic Stroke in Children and Adults With Sickle Cell Anemia: The Post-STOP Cohort.

Fox CK, Leykina L, Hills NK, Kwiatkowski JL, Kanter J, Strouse JJ, Voeks JH, Fullerton HJ, Adams RJ; Post-STOP Study Group. Fox CK, et al. Among authors: kanter j. Stroke. 2022 Nov;53(11):e463-e466. doi: 10.1161/STROKEAHA.122.038651. Epub 2022 Oct 7. Stroke. 2022. PMID: 36205141

47

Improving Outcomes for Patients With Sickle Cell Disease in the United States: Making the Case for More Resources, Surveillance, and Longitudinal Data.

Kanter J, Meier ER, Hankins JS, Paulukonis ST, Snyder AB. Kanter J, et al. JAMA Health Forum. 2021 Oct 1;2(10):e213467. doi: 10.1001/jamahealthforum.2021.3467. JAMA Health Forum. 2021. PMID: 36218900 Free article. Review.

48

Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study.

Badawy SM, DiMartino L, Brambilla D, Klesges L, Baumann A, Burns E, DeMartino T, Jacobs S, Khan H, Nwosu C, Shah N, Hankins JS; Sickle Cell Disease Implementation Consortium. Badawy SM, et al. JMIR Form Res. 2022 Oct 14;6(10):e41415. doi: 10.2196/41415. JMIR Form Res. 2022. PMID: 36240004 Free PMC article.

49

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease.

Kanter J, Brown RC, Norris C, Nair SM, Kutlar A, Manwani D, Shah N, Tanaka C, Bodla S, Sanchez-Olle G, Albers U, Liles D. Kanter J, et al. Blood Adv. 2023 Mar 28;7(6):943-952. doi: 10.1182/bloodadvances.2022008209. Blood Adv. 2023. PMID: 36355805 Free PMC article.

50

What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease.

Lamont AE, Hsu LL, Jacobs S, Gibson R, Treadwell M, Chen Y, Lottenberg R, Axelrod K, Varughese T, Melvin C, Smith S, Chukwudozie IB, Kanter J; Sickle Cell Disease Implementation Consortium. Lamont AE, et al. Among authors: kanter j. PLoS One. 2022 Nov 11;17(11):e0272204. doi: 10.1371/journal.pone.0272204. eCollection 2022. PLoS One. 2022. PMID: 36367870 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

443 results

Search Page